For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| License and other revenue | 0 | 0 | 15,000,000 | 0 |
| Research and development | 41,563,000 | 42,741,000 | 33,443,000 | 60,874,000 |
| General and administrative | 12,227,000 | 11,912,000 | 12,334,000 | 13,706,000 |
| Loss from operations | -53,790,000 | -54,653,000 | -30,777,000 | -74,580,000 |
| Interest and investment income | 3,765,000 | 4,380,000 | 7,890,000 | 3,718,000 |
| Interest expense | 2,890,000 | 2,884,000 | 2,877,000 | 2,504,000 |
| Loss on extinguishment of debt | - | - | - | -8,524,250 |
| Other non-operating income (expense), net | -1,810,000 | 3,592,000 | 1,026,000 | -3,968,000 |
| Loss before income taxes | -54,725,000 | -49,565,000 | -24,738,000 | -110,279,000 |
| Income tax expense | 166,000 | 778,000 | 1,397,000 | 1,050,000 |
| Net loss | -54,891,000 | -50,343,000 | -26,135,000 | -111,329,000 |
| Foreign currency translation adjustment | 691,000 | -479,000 | 643,000 | 1,721,000 |
| Unrealized gain on available for sale securities, net of taxes | - | - | - | 397,000 |
| Unrealized (loss) gain on available for sale marketable securities, net of reclassification adjustment and tax | 318,000 | -5,000 | -2,781,000 | - |
| Other comprehensive (loss) income | 1,009,000 | -484,000 | -2,138,000 | 2,118,000 |
| Total comprehensive loss | -53,882,000 | -50,827,000 | -28,273,000 | -109,211,000 |
| Net loss per ordinary share - basic (in dollars per share) | -0.41 | -0.38 | -0.2 | -0.91 |
| Net loss per ordinary share - diluted (in dollars per share) | -0.41 | -0.38 | -0.2 | -0.91 |
| Weighted average ordinary shares outstanding - basic (in shares) | 134,163,492 | 133,677,405 | 133,033,541 | -211,157,357 |
| Weighted average ordinary shares outstanding - diluted (in shares) | 134,163,492 | 133,677,405 | 133,033,541 | -211,157,357 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)